Connor, Clark & Lunn Investment Management Ltd. Fulcrum Therapeutics, Inc. Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $26 Billion
- Q2 2025
A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Fulcrum Therapeutics, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 342,547 shares of FULC stock, worth $3.31 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
342,547
Previous 217,749
57.31%
Holding current value
$3.31 Million
Previous $627,000
275.76%
% of portfolio
0.01%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding FULC
# of Institutions
129Shares Held
55.5MCall Options Held
886KPut Options Held
93.3K-
Ra Capital Management, L.P. Boston, MA10.2MShares$98.7 Million1.54% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA5.25MShares$50.7 Million7.36% of portfolio
-
Suvretta Capital Management, LLC New York, NY5.08MShares$49 Million1.2% of portfolio
-
Black Rock Inc. New York, NY4.8MShares$46.3 Million0.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA4.59MShares$44.3 Million0.06% of portfolio
About Fulcrum Therapeutics, Inc.
- Ticker FULC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,038,900
- Market Cap $502M
- Description
- Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystro...